These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
248 related items for PubMed ID: 8723140
1. A randomized, double-blind, placebo-controlled study to evaluate botulinum toxin type A in essential hand tremor. Jankovic J, Schwartz K, Clemence W, Aswad A, Mordaunt J. Mov Disord; 1996 May; 11(3):250-6. PubMed ID: 8723140 [Abstract] [Full Text] [Related]
3. Botulinum toxin type A as migraine preventive treatment in patients previously failing oral prophylactic treatment due to compliance issues. Cady R, Schreiber C. Headache; 2008 Jun; 48(6):900-13. PubMed ID: 18047501 [Abstract] [Full Text] [Related]
4. Botulinum toxin type A for upper limb spasticity following stroke: an open-label study with individualised, flexible injection regimens. Slawek J, Bogucki A, Reclawowicz D. Neurol Sci; 2005 Apr; 26(1):32-9. PubMed ID: 15877185 [Abstract] [Full Text] [Related]
5. Botulinum toxin type a prophylactic treatment of episodic migraine: a randomized, double-blind, placebo-controlled exploratory study. Aurora SK, Gawel M, Brandes JL, Pokta S, Vandenburgh AM, BOTOX North American Episodic Migraine Study Group. Headache; 2007 Apr; 47(4):486-99. PubMed ID: 17445098 [Abstract] [Full Text] [Related]
7. A double-blind, randomized, controlled study of botulinum toxin type A in MS-related tremor. Van Der Walt A, Sung S, Spelman T, Marriott M, Kolbe S, Mitchell P, Evans A, Butzkueven H. Neurology; 2012 Jul 03; 79(1):92-9. PubMed ID: 22753445 [Abstract] [Full Text] [Related]
8. [Botulinum toxin treatment of hip adductor spasticity in multiple sclerosis]. Wissel J, Entner T. Wien Klin Wochenschr; 2001 Jul 03; 113 Suppl 4():20-4. PubMed ID: 15506048 [Abstract] [Full Text] [Related]
9. Bilateral, double-blind, randomized comparison of 3 doses of botulinum toxin type A and placebo in patients with crow's feet. Lowe NJ, Lask G, Yamauchi P, Moore D. J Am Acad Dermatol; 2002 Dec 03; 47(6):834-40. PubMed ID: 12451366 [Abstract] [Full Text] [Related]
10. Efficacy and safety of mixed amphetamine salts extended release (Adderall XR) in the management of attention-deficit/hyperactivity disorder in adolescent patients: a 4-week, randomized, double-blind, placebo-controlled, parallel-group study. Spencer TJ, Wilens TE, Biederman J, Weisler RH, Read SC, Pratt R. Clin Ther; 2006 Feb 03; 28(2):266-79. PubMed ID: 16678648 [Abstract] [Full Text] [Related]
11. Botulinum toxin A may be efficacious as treatment for jaw tremor in Parkinson's disease. Schneider SA, Edwards MJ, Cordivari C, Macleod WN, Bhatia KP. Mov Disord; 2006 Oct 03; 21(10):1722-4. PubMed ID: 16817198 [Abstract] [Full Text] [Related]
12. A randomised, double-blind, dose-ranging study to evaluate efficacy and safety of three doses of botulinum toxin type A (Botox) for the treatment of spastic foot. Mancini F, Sandrini G, Moglia A, Nappi G, Pacchetti C. Neurol Sci; 2005 Apr 03; 26(1):26-31. PubMed ID: 15877184 [Abstract] [Full Text] [Related]
13. Treatment of whiplash associated neck pain [corrected] with botulinum toxin-A: a pilot study. Freund BJ, Schwartz M. J Rheumatol; 2000 Feb 03; 27(2):481-4. PubMed ID: 10685817 [Abstract] [Full Text] [Related]
14. A double-blind, randomized, placebo-controlled comparison of botulinum toxin type a injection sites and doses in the prevention of episodic migraine. Saper JR, Mathew NT, Loder EW, DeGryse R, VanDenburgh AM, BoNTA-009 Study Group. Pain Med; 2007 Sep 03; 8(6):478-85. PubMed ID: 17716321 [Abstract] [Full Text] [Related]
15. A multicenter, randomized, double-blind, placebo-controlled study of efficacy and safety of 3 doses of botulinum toxin A in the treatment of glabellar lines. Ascher B, Zakine B, Kestemont P, Baspeyras M, Bougara A, Santini J. J Am Acad Dermatol; 2004 Aug 03; 51(2):223-33. PubMed ID: 15280841 [Abstract] [Full Text] [Related]
16. Botulinum toxin type a for the prophylaxis of chronic daily headache: subgroup analysis of patients not receiving other prophylactic medications: a randomized double-blind, placebo-controlled study. Dodick DW, Mauskop A, Elkind AH, DeGryse R, Brin MF, Silberstein SD, BOTOX CDH Study Group. Headache; 2005 Apr 03; 45(4):315-24. PubMed ID: 15836567 [Abstract] [Full Text] [Related]
17. Botulinum toxin type A in the treatment of primary axillary hyperhidrosis: a 52-week multicenter double-blind, randomized, placebo-controlled study of efficacy and safety. Lowe NJ, Glaser DA, Eadie N, Daggett S, Kowalski JW, Lai PY, North American Botox in Primary Axillary Hyperhidrosis Clinical Study Group. J Am Acad Dermatol; 2007 Apr 03; 56(4):604-11. PubMed ID: 17306417 [Abstract] [Full Text] [Related]
18. Efficacy and safety of 3- and 5-injection patterns (30 and 50 U) of botulinum toxin A (Dysport) for the treatment of wrinkles in the glabella and the central forehead region. Rzany B, Ascher B, Fratila A, Monheit GD, Talarico S, Sterry W. Arch Dermatol; 2006 Mar 03; 142(3):320-6. PubMed ID: 16549707 [Abstract] [Full Text] [Related]
19. Intramuscular injection of botulinum toxin for the treatment of wrist and finger spasticity after stroke. Jahangir AW, Tan HJ, Norlinah MI, Nafisah WY, Ramesh S, Hamidon BB, Raymond AA. Med J Malaysia; 2007 Oct 03; 62(4):319-22. PubMed ID: 18551937 [Abstract] [Full Text] [Related]
20. BotB (botulinum toxin type B): evaluation of safety and tolerability in botulinum toxin type A-resistant cervical dystonia patients (preliminary study). Truong DD, Cullis PA, O'Brien CF, Koller M, Villegas TP, Wallace JD. Mov Disord; 1997 Sep 03; 12(5):772-5. PubMed ID: 9380065 [Abstract] [Full Text] [Related] Page: [Next] [New Search]